Crinetics Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Crinetics Pharmaceuticals de 24.7% y 52.2% por año respectivamente. Se prevé que el BPA crezca en un 27.4% al año. Se espera que la rentabilidad financiera sea de -47.5% en 3 años.

Información clave

24.7%

Tasa de crecimiento de los beneficios

27.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.1%
Tasa de crecimiento de los ingresos	52.2%
Rentabilidad financiera futura	-47.5%
Cobertura de analistas	Good
Última actualización	27 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress

Apr 24

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Jan 19

Crinetics Pharmaceuticals appoints Garlan Adams as general counsel

Jun 16

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

May 13

Crinetics Pharmaceuticals EPS misses by $0.04

May 06

Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?

Mar 21

Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth

Jan 27

Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares

Dec 06

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:CRNX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	88	-276	-252	-224	7
12/31/2025	28	-272	-214	-210	11
12/31/2024	1	-245	-209	-223	11
12/31/2023	4	-215	-171	-166	N/A
9/30/2023	5	-199	-167	-163	N/A
6/30/2023	5	-184	-161	-160	N/A
3/31/2023	4	-175	-144	-142	N/A
12/31/2022	5	-164	-117	-115	N/A
9/30/2022	5	-150	-104	-103	N/A
6/30/2022	5	-136	-91	-90	N/A
3/31/2022	4	-119	-82	-82	N/A
12/31/2021	1	-108	-89	-89	N/A
9/30/2021	N/A	-98	-82	-82	N/A
6/30/2021	N/A	-89	-74	-74	N/A
3/31/2021	N/A	-79	-70	-70	N/A
12/31/2020	0	-74	-62	-62	N/A
9/30/2020	0	-67	-60	-60	N/A
6/30/2020	1	-63	-55	-55	N/A
3/31/2020	1	-59	-52	-52	N/A
12/31/2019	1	-50	-47	-46	N/A
9/30/2019	2	-44	-40	-39	N/A
6/30/2019	2	-38	-32	-31	N/A
3/31/2019	2	-31	-24	-23	N/A
12/31/2018	2	-27	-21	-19	N/A
9/30/2018	2	-21	-17	-16	N/A
6/30/2018	2	-16	-13	-13	N/A
3/31/2018	2	-12	-11	-11	N/A
12/31/2017	2	-9	-10	-9	N/A
12/31/2016	1	-6	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CRNX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CRNX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CRNX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (52.2% al año) de CRNX crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (52.2% al año) de CRNX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: CRNX se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Crinetics Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.8% to US$57.23

Price target increased by 9.1% to US$54.46

Consensus revenue estimates decrease by 88%, EPS upgraded

Consensus revenue estimates decrease by 89%, EPS upgraded

Price target increased by 8.2% to US$46.78

Consensus revenue estimates fall by 18%

Recent updates

Chief Development Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.8% to US$57.23

Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly

Price target increased by 9.1% to US$54.46

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Consensus revenue estimates decrease by 88%, EPS upgraded

Consensus revenue estimates decrease by 89%, EPS upgraded

Chief Medical Officer notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Chief Medical Officer notifies of intention to sell stock

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly

Price target increased by 8.2% to US$46.78

Consensus revenue estimates fall by 18%

Price target decreased by 7.4% to US$43.63

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$1.0m worth of stock

Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023

Founder notifies of intention to sell stock

Consensus revenue estimates increase by 154%

Chief Development Officer notifies of intention to sell stock

Chief Development Officer recently sold US$133k worth of stock

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 12%

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Founder & Chief Scientific Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program

Consensus revenue estimates fall by 37%

High number of new directors

Founder & Chief Scientific Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study

Founder & Chief Scientific Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

Crinetics Pharmaceuticals Appoints Dana Pizzuti as Chief Development Officer

Founder & Chief Scientific Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Crinetics Pharmaceuticals Announces New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

Consensus revenue estimates fall by 28%

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Independent Director exercised options and sold US$111k worth of stock

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

High number of new and inexperienced directors

Consensus revenue estimates fall by 13%

Crinetics Pharmaceuticals, Inc. Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

Consensus revenue estimates increase by 46%

High number of new and inexperienced directors

Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock